Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA4 | P22748 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | TOP2A | P11388 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | VCP | P55072 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535310 | 1.00 | CA12 (0.56) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4134044 | 0.86 | TOP2A (0.55) | TOP2AKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7101273 | 0.86 | TOP2A (0.55) | TOP2AKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8028311 | 0.86 | TOP2A (0.51) | TOP2AKMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL5285372 | 0.82 | MAPT (0.44) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4137665 | 0.80 | ALDH1A1 (0.65) | KMT2AVCPALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4137658 | 0.80 | ALDH1A1 (0.65) | KMT2AVCPALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14010503 | 0.80 | CA12 (0.57) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1535326 | 0.80 | MAPT (0.52) | KMT2AALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL10019901 | 0.77 | MAPT (0.51) | KMT2AALDH1A1SMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339665-B1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX SA (FR) | 2007-12-19 | — | — | EP | claimed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | claimed |
| EP-1339665-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | Nicox S.A. (FR) | 2003-09-03 | — | — | EP | claimed |
| WO-2002030866-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | claimed |
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| EP-1339665-B1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX SA (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| EP-1339665-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | Nicox S.A. (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002030866-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | CA12 3168/4885CA1 2096/4885CA2 1920/4885 |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | TPMT, NOX1, CBR1 | CA12 2851/4885CA1 2822/4885CA2 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.